VR Adviser’s Pliant Therapeutics PLRX Stock Holding History

VR Adviser’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-288,949	Closed	-$5.01M	–	39
2023 Q3	$5.01M	Hold	288,949	–	–	0.53%	31
2023 Q2	$5.24M	Sell	288,949 -1,141,051	-80%	-$27M	0.84%	24
2023 Q1	$38M	Buy	1,430,000 +350,000	+32%	+$9.96M	7.43%	5
2022 Q4	$20.9M	Hold	1,080,000	–	–	3.52%	10
2022 Q3	$22.6M	Buy	+1,080,000	New	+$20.7M	3.48%	7

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

VR Adviser's PLRX Position: Q4 2023 in Review

VR Adviser sold out of Pliant Therapeutics (PLRX) in Q4 2023, closing a stake of 288,949 shares — an estimated $5.01M sold.

VR Adviser first reported a position in PLRX in Q3 2022 and held it in 5 quarters. The position peaked at $38M in Q1 2023. 134 funds tracked by Wall St. Rank hold PLRX as of Q4 2023.

VR Adviser reported no remaining Pliant Therapeutics position as of Q4 2023 after selling out during the quarter.
VR Adviser sold 288,949 Pliant Therapeutics shares in Q4 2023, an estimated $5.01M.
VR Adviser first reported a position in Pliant Therapeutics in Q3 2022 and held it in 5 quarters.
VR Adviser's Pliant Therapeutics position peaked at $38M in Q1 2023.
134 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2023.

Based on VR Adviser's 13F filing for Q4 2023, filed 14 Feb 2024.